Story

Oxford BioMedica Shares Plunge After Slashing Full-Year Revenue Forecast

ENTHMSVIIDZHZH-TWJAKOHI
Aug 7, 20261 min read
Oxford BioMedica Shares Plunge After Slashing Full-Year Revenue Forecast
Text size
Background

Shares of Oxford BioMedica (LSE:OXB) plummeted more than 18% in morning trading after the company issued a significant downward revision to its full-year 2026 revenue guidance, surprising investors.

Guidance Cut

The contract development and manufacturing organization (CDMO) now anticipates full-year revenues in the range of £180 million to £200 million. This is a substantial reduction from its previous forecast of £220 million to £240 million.

Oxford BioMedica attributed the approximately £40 million cut at the midpoint to a "short-term shift in client ordering behaviour." The revision represents a significant blow to management's credibility, as the company had reaffirmed the higher guidance as recently as March 2026.

Investor Confidence Shaken

Sample IUX Markets – In-articleAd

The sudden reversal is particularly jarring for the market because management had previously stated that 60% of the original revenue forecast was already secured through contracted client orders. Today's announcement forces a reassessment of the company's near-term growth trajectory and forecasting accuracy.

The sell-off appeared to be driven entirely by the company-specific news. Broader market conditions were neutral, with no major economic data releases or competitor announcements identified as contributing factors, according to Investing.com.

Market Reaction

The stock fell as much as 18.4% to a session low of 441.5 pence. The sharp decline pushes the share price near its 52-week low of 430p, a stark contrast to its 52-week high of 950p.

Read next

More on Stocks
Back to latest news

LATEST